Our drug programmes



A summary statement covering the latest drug programme activity by Synairgen


Peer-reviewed data from Synairgen’s SG016 trial was published in The Lancet Respiratory Medicine journal on 12 November 2020. The SG016 trial randomised 101 hospitalised COVID-19 patients to either SNG001, Synairgen’s inhaled formulation of interferon beta-1a, or placebo. Positive topline results from the trial were originally announced on 20 July 2020, with more detailed results of primary endpoint analyses disclosed in the Company’s 2020 Interim Results on 29 September 2020.

The full title of the publication in the Lancet Respiratory Medicine is: “Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial”, and can be accessed here.

Results from the Home Cohort of the SG016 trial of inhaled interferon beta in COVID-19 patients, alongside an analysis of combined data from the Hospital and Home Cohorts, were announced by Synairgen on 30 April 2021. The results of the trial and combined cohort analysis can be accessed here. Synairgen plans to present the findings at an upcoming medical conference and submit the findings for publication in a peer-reviewed journal.

Synairgen’s Phase III Trial (SG018) evaluating inhaled interferon beta in hospitalised COVID-19 patients is currently underway. The trial is a randomised, placebo-controlled study being conducted in approximately 20 countries, enrolling a total of 610 COVID-19 patients.

Results from in vitro studies showing the antiviral activity of SNG001 against two SARS-CoV-2 variants were announced on 24 May 2021. Full details can be accessed here.